Amiloride is a therapy used for treating high blood pressure and heart conditions. Research has suggested that amiloride — as a sodium channel blocker — may have a neuroprotective effect in multiple sclerosis (MS) because it blocks sodium and calcium from entering the nerve cells, which could lead to axon damage.

A pilot study involving patients with primary progressive multiple sclerosis (PPMS) showed that participants taking amiloride experienced less nerve damage, less loss of brain volume, and a slower decrease of disability compared to the year prior to treatment.

Amiloride is one of three drugs being investigated in a Phase 2 study called MS-SMART (NCT0190259). The study recruited 440 people with SPMS to test the safety and effectiveness of three different drugs – riluzole, amiloride, and fluoxetine — over two years. This study is expected to end in 2018.

Common side effects of amiloride are diarrhea, headache, loss of appetite, nausea, and weakness.

Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

  1. https://www.mssociety.org.uk/ms-research/treatments-in-the-pipeline/amiloride
  2. https://www.ncbi.nlm.nih.gov/pubmed/23365093
  3. https://www.mstrust.org.uk/a-z/amiloride